Online inquiry

IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2322MR)

This product GTTS-WQ2322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD200 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001004196.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4345
UniProt ID P41217
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3987MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ1714MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ14585MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ1348MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ15147MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ14153MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ5227MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ187MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW